Gottlieb Lays Out Risk-Based Approach For Compounding GMPs, State MOU

February 1, 2018 at 12:36 PM
FDA Commissioner Scott Gottlieb told legislators Tuesday (Jan. 30) that FDA will take a risk-based approach to both the yet-to-be-finalized 503B-lite category of compounders and the new model agreement between states and FDA on oversight of compounders that ship products out of state. Gottlieb emphasized that FDA will tailor its requirements depending not just on the size of an operation but the products being compounded and their risk to patients. Gottlieb also faced questions regarding the newly finalized guidance on...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.